Novo Nordisk AI Strategy: OpenAI Across the Business by 2026
How Novo Nordisk uses AI on its own work: OpenAI across the business, AI fluency for staff and 90% faster clinical report writing. Updated November 2026.
Danish pharmaceutical company focused on diabetes and obesity, maker of Ozempic and Wegovy
Novo Nordisk has no standalone AI strategy document. AI is part of its company-wide transformation, set out in its April 2026 partnership with OpenAI.
Read the company sourceWhere Novo Nordisk Is Going with AI
Novo Nordisk wants AI in everyday work across the company. President and CEO Mike Doustdar announced a strategic partnership with OpenAI in April 2026 that covers research, manufacturing, supply chain and commercial work, with full integration targeted by the end of 2026.
Doustdar ties AI to the scale of analysis. He said: “Integrating AI in our everyday work gives us the ability to analyze datasets at a scale that was previously impossible.”
Novo Nordisk has no standalone AI strategy document. This profile draws on the partnership announcement, news reports and a supplier case study.
The focus has four parts.
- Research: analysis of complex biological and clinical datasets to find patterns and drug targets
- Clinical documentation: NovoScribe, an internal platform that drafts clinical study reports and other regulated documents
- Manufacturing and supply chain: pilots with OpenAI ahead of scaled deployment
- Commercial: pilots with OpenAI in commercial operations
What It Takes: An OpenAI Partnership, Upskilling and In-House Builds
Upskilling is central to the OpenAI deal. OpenAI will help Novo Nordisk build AI fluency across its global organization, with strict data governance and human oversight, according to BioPharm International. The plan treats AI adoption as change management across the whole company.
A small in-house team built NovoScribe. Eleven people built the platform with Claude Code, according to an Anthropic case study. Waheed Jowiya, Digitalization Strategy Director at the time, said: “Claude has helped us cut writing times on CSRs by 90%.”
Novo Nordisk cut about 9,000 jobs in 2025. It announced the cuts, about 11% of its workforce, in September 2025 to save about $1.25bn a year, according to R&D World. Doustdar said the OpenAI partnership would make scientists faster and slow future hiring.
Headcount fell 10% in 2025, to 68,794. It had risen 40% from 2022 to 2024.
AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):
- Fluency floor: Not published. OpenAI is to build AI fluency across the organization, and Novo Nordisk has set no public standard for all staff.
- Highest level evidenced: Level 3 (Integrating), company-claimed. NovoScribe drafts clinical study reports inside the documentation workflow.
- Portfolio design: Novo Nordisk pairs one company-wide AI partner with in-house builds for regulated documents.
How Novo Nordisk Measures Results
Novo Nordisk reports results for clinical documentation, without a total. The figures below are company-claimed, from the Anthropic case study:
- Clinical study reports: writing time cut by 90%
- Device verification protocols: 95% fewer resources needed
- Review cycles: cut in half
Gaps remain. Novo Nordisk has reported no results from the OpenAI partnership and gives no AI value figure. Publishing both is the step from AI adoption to AI value.
Next markers: full integration with OpenAI by the end of 2026, AI for regulatory submissions, how AI changes hiring and headcount for 2026.
Change log
- September 2025: Novo Nordisk announces about 9,000 job cuts.
- April 2026: Novo Nordisk announces a strategic partnership with OpenAI across the business.
The Bottom Line
- Disclosure: 4 of 4. Novo Nordisk answers all four questions, the last in part, with documentation results from a supplier case study and no total.
- One AI partner covers the whole business, with integration due by the end of 2026.
- In-house builds cut clinical report writing time by 90%.
- Level 3 is evidenced in clinical documentation, on company-claimed figures.
- The say-do gap is people. AI is set to slow hiring after deep job cuts, and Novo Nordisk has published no plan for how roles change.
- Watch the end of 2026. The test is whether full integration with OpenAI lands on time.
Revenue, Headcount and Revenue per Employee
What the numbers show: Net sales rose 75% from 2022 to 2025 on demand for its diabetes and obesity medicines. Headcount rose 40% to 2024, then fell 10% in 2025 after Novo Nordisk announced about 9,000 job cuts, so revenue per employee rose 38%, to about DKK 4.49m. These figures do not show that AI caused any change.
Revenue, headcount and revenue per employee, FY2022 to FY2025
- FY2022: DKK 177.0bn revenue, 54,393 employees, DKK 3.25M per employee
- FY2023: DKK 232.3bn revenue, 63,370 employees, DKK 3.67M per employee
- FY2024: DKK 290.4bn revenue, 76,302 employees, DKK 3.81M per employee
- FY2025: DKK 309.1bn revenue, 68,794 employees, DKK 4.49M per employee
Change, FY2022 to FY2025: revenue up 75%, headcount up 26%, revenue per employee up 38%.
Notes: Revenue is net sales, as reported. Headcount is at year-end. Average headcount in 2025 was 76,343, higher than the year-end figure, because the job cuts came late in the year. Trend figures stay in DKK so exchange-rate moves do not distort them. At the 2025 average exchange rate, latest revenue per employee is about $680k.
These figures give context on scale and productivity. They do not show that AI caused any change. Sources: Novo Nordisk 20-F filings.
How Novo Nordisk Compares with European Pharma Peers
We looked at how Novo Nordisk compares with other European pharmaceutical companies in the index. Here is how they stack up.
| Company | Disclosure | AI owner | Fluency floor | Governance | AI value reported | Revenue per employee |
|---|---|---|---|---|---|---|
| AstraZeneca | 4 of 4 | No single owner named; finance picks pilots to scale | Not published; Silver certification above a set grade | Finance reviews which pilots scale | No: certifications and pilots only | $611k |
| GSK | 3 of 4 | SVP Global Head of AI and Machine Learning | Not published | Little published | No: savings plan with no AI share | $631k |
| Novartis | 2 of 4 | CIO; no Chief AI Officer | Role-based paths, no company-wide floor | Published, a standing board topic | Linked to lower costs, no figure | $725k |
| Novo Nordisk | 4 of 4 | CEO-led OpenAI partnership | Not published; OpenAI to build AI fluency | Data governance and human oversight, stated | Results by use case, no total | $680k |
| Roche | 4 of 4 | Chief Digital and Technology Officer; research head leads research AI | Not published | Little published | AI share of research decisions, no value | $729k |
| Sanofi | 4 of 4 | Chief Digital Officer | Level 1, about 80% use | RAISE framework, five pillars | Results by use case, no total | $644k |
Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. See all companies in the AI Strategy Index.
Frequently Asked Questions
What is Novo Nordisk’s AI strategy for its own work?
Novo Nordisk is integrating AI across research, manufacturing, supply chain and commercial work through a partnership with OpenAI. It targets full integration by the end of 2026.
Who leads AI at Novo Nordisk?
President and CEO Mike Doustdar announced the OpenAI partnership in April 2026. The sources reviewed name no dedicated AI leader.
What is NovoScribe?
NovoScribe is Novo Nordisk’s internal platform for clinical documentation, built with Claude. It cut writing time for clinical study reports by 90%, according to an Anthropic case study.
Is Novo Nordisk cutting jobs because of AI?
The sources reviewed do not link Novo Nordisk’s 2025 job cuts to AI. Doustdar said the OpenAI partnership would slow future hiring.
How is this profile put together?
Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.
About the AI Strategy Index
The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.
See all company profiles